OncoPharm

Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians learn (and what can't we learn) from these? We read through two examples for just this purpose.

Example 1: https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer

Example 2: https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-reports-93-clinical-benefit-rate-mipletamig-triplet

Possible Help with Drug Shortages: https://www.angelsforchange.org

Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.

Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week's pod has everything:
1. DDI information and dosing for daraxonrasib, now FDA approved and commercially available for pancreatic cancer
2. A new standard of care (?) in HER(+) gastric cancers, and more nuance on HER2 positivity. And lots of diarrhea.
3. The largest RCT in primary CNS lymphoma

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

CELMoDs are here, but are they here to stay?

CELMoD/IMiD review article: https://doi.org/10.1080/17474086.2024.2382897

Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Overview of renal cell carcinoma

Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm